Authorized purpose: The NvisionVLE Imaging System is an imaging tool for evaluating human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization and marking areas of tissue. The software provides segmentation and display of common imaging features including hyper-reflective surface, layering, and hypo-reflective structures. Safety and effectiveness for diagnostic analysis of normal versus a specific abnormality or disease have not been evaluated.
Clinical role
OCT acquisition, real-time visualization, image manipulation, measurement, and annotation under professional control.
Images and patients
Optical Coherence Tomography · Human tissue microstructure, including esophageal tissue
Key limitation
Keep in mind: The exact labeling states that safety and effectiveness for diagnostic analysis of a specific abnormality or disease have not been evaluated; use is limited to the labeled tissue-imaging and marking workflow.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The NvisionVLE Imaging System is an imaging tool for evaluating human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization and marking areas of tissue. The software provides segmentation and display of common imaging features including hyper-reflective surface, layering, and hypo-reflective structures. Safety and effectiveness for diagnostic analysis of normal versus a specific abnormality or disease have not been evaluated.
Which images or clinical context are in scope?Modality: Optical Coherence Tomography Anatomy or clinical context: Human tissue microstructure, including esophageal tissue Input: OCT data from the supported imaging system, probe, tissue, and procedure configuration.
Who uses it?Intended users: Trained physicians and procedural or pathology professionals within the labeled tissue workflow.
What does the software produce?Output: Two-dimensional or volumetric cross-sectional OCT images, markers, annotations, and measurements for professional review.
What is its most important limitation?Key limitation: The exact labeling states that safety and effectiveness for diagnostic analysis of a specific abnormality or disease have not been evaluated; use is limited to the labeled tissue-imaging and marking workflow.
Clinical takeaway. Clinical role: The NvisionVLE Imaging System is an imaging tool for evaluating human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization and marking areas of tissue. The software provides segmentation and display of common imaging features including hyper-reflective surface, layering, and hypo-reflective structures. Safety and effectiveness for diagnostic analysis of normal versus a specific abnormality or disease have not been evaluated.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports bench testing of Image and Visualization Enhancement feature detection against ROIs labeled by trained experts, using a sequestered subset (~40%) of the 1000-patient 18-site NvisionVLE Clinical Registry study. Table 1 reports true positive and true negative detection fractions (%) of 92.9 (235/253) and 95.0 (209/220) for tissue surface, 89.6 (205/229) and 97.8 (220/225) for layering, and 91.1 (175/192) and 92.9 (247/266) for hypo-reflective structures; all exceeded their target values. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The NvisionVLE Imaging System is an imaging tool for evaluating human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization and marking areas of tissue. The software provides segmentation and display of common imaging features including hyper-reflective surface, layering, and hypo-reflective structures. Safety and effectiveness for diagnostic analysis of normal versus a specific abnormality or disease have not been evaluated.
The exact labeling states that safety and effectiveness for diagnostic analysis of a specific abnormality or disease have not been evaluated; use is limited to the labeled tissue-imaging and marking workflow.
The exact FDA document reports bench testing of Image and Visualization Enhancement feature detection against ROIs labeled by trained experts, using a sequestered subset (~40%) of the 1000-patient 18-site NvisionVLE Clinical Registry study. Table 1 reports true positive and true negative detection fractions (%) of 92.9 (235/253) and 95.0 (209/220) for tissue surface, 89.6 (205/229) and 97.8 (220/225) for layering, and 91.1 (175/192) and 92.9 (247/266) for hypo-reflective structures; all exceeded their target values. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "A series of bench tests were conducted to assess the performance and safety of the device." … "Data used for testing was obtained from a sequestered subset (~40%) of the 1000-patient 18-site NvisionVLE Clinical Registry study. Here, patients were randomly chosen and regions of interest (ROI), defined as 30° segments of a 360° transverse image, were selected for testing.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports bench testing of Image and Visualization Enhancement feature detection against ROIs labeled by trained experts, using a sequestered subset (~40%) of the 1000-patient 18-site NvisionVLE Clinical Registry study. Table 1 reports true positive and true negative detection fractions (%) of 92.9 (235/253) and 95.0 (209/220) for tissue surface, 89.6 (205/229) and 97.8 (220/225) for layering, and 91.1 (175/192) and 92.9 (247/266) for hypo-reflective structures; all exceeded their target values. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "A series of bench tests were conducted to assess the performance and safety of the device." … "Data used for testing was obtained from a sequestered subset (~40%) of the 1000-patient 18-site NvisionVLE Clinical Registry study. Here, patients were randomly chosen and regions of interest (ROI), defined as 30° segments of a 360° transverse image, were selected for testing.". Read from the exact FDA decision document on 2026-11-14.
Standalone ROI-level sensitivity (true positive detection fraction) on a sequestered subset of NvisionVLE Clinical Registry data: tissue surface 92.9% (lower limit of exact 95% CI 89.0%); hypo-reflective structures 91.1% (lower limit 86.2%).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "the tissue surface detection showed a true positive detection fraction of 92.9 % (Lower Limit of Exact 95% Two-Sided Confidence Interval 89.0%)" … "The Hypo-Reflective Structures showed a true positive detection fraction of 91.1% (Lower Limit of Exact 95% Two-Sided Confidence Interval 86.2%)". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Standalone ROI-level specificity (true negative detection fraction) on a sequestered subset of NvisionVLE Clinical Registry data: tissue surface 95.0% (lower limit of exact 95% CI 91.2%); hypo-reflective structures 92.9% (lower limit 89.1%).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "the tissue surface detection showed a true positive detection fraction of 92.9 % (Lower Limit of Exact 95% Two-Sided Confidence Interval 89.0%) and true negative detection fraction of 95.0% (Lower Limit of Exact 95% Two-Sided Confidence Interval 91.2%)" … "The Hypo-Reflective Structures showed a true positive detection fraction of 91.1% (Lower Limit of Exact 95% Two-Sided Confidence Interval 86.2%) and true negative detection fraction of 92.9% (Lower Limit of Exact 95% Two-Sided Confidence Interval 89.1%)". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K182616 FDA decision evidence package for NvisionVLE Imaging System, NvisionVLE Optical Probe, NvisionVLE Inflation System
DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
PopulationHuman tissue microstructure, including esophageal tissue
Scopeexact submission
Tested versionNvisionVLE Imaging System, NvisionVLE Optical Probe, NvisionVLE Inflation System configuration described in K182616
IndependenceSponsor or vendor study
K182616
FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K182616 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: OCT data from the supported imaging system, probe, tissue, and procedure configuration.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact public FDA decision material does not establish a complete integration contract. Confirm supported inputs, outputs, identity, routing, archive behavior, audit behavior, and downtime locally.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Two-dimensional or volumetric cross-sectional OCT images, markers, annotations, and measurements for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Two-dimensional or volumetric cross-sectional OCT images, markers, annotations, and measurements for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Only trained physicians and procedural or pathology professionals within the labeled tissue workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K182616 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact labeling states that safety and effectiveness for diagnostic analysis of a specific abnormality or disease have not been evaluated; use is limited to the labeled tissue-imaging and marking workflow.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.
The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The exact labeling states that safety and effectiveness for diagnostic analysis of a specific abnormality or disease have not been evaluated; use is limited to the labeled tissue-imaging and marking workflow.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
exact submission · checked 2026-09-04
No exact-product price or reimbursement determination was promoted.
Monitor K182616 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact labeling states that safety and effectiveness for diagnostic analysis of a specific abnormality or disease have not been evaluated; use is limited to the labeled tissue-imaging and marking workflow.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact public FDA decision material does not establish a complete integration contract. Confirm supported inputs, outputs, identity, routing, archive behavior, audit behavior, and downtime locally.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: Abbott OPTIS Mobile or Integrated Next with Ultreon 3.0 processes compatible coronary intravascular OCT data to support visualization, measurement, and interventional assessment of coronary vessels.
Authorized purpose: OPTIS Mobile Next Imaging System and OPTIS Integrated Next Imaging System acquire, display, and analyze intravascular optical coherence tomography images for trained professionals in the labeled coronary and interventional workflow.
Authorized purpose: OTIS 2.1 is indicated as an imaging tool for evaluating excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image-review manipulation software for identifying and annotating regions of interest.
Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.